- Home
- LEU vs KROS Comparison
LEU vs KROS Comparison
Compare LEU & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- KROS
- Stock Information
- Founded
- LEU 1998
- KROS 2015
- Country
- LEU United States
- KROS United States
- Employees
- LEU N/A
- KROS N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- KROS Health Care
- Exchange
- LEU Nasdaq
- KROS Nasdaq
- Market Cap
- LEU 1.2B
- KROS 589.8M
- IPO Year
- LEU 1998
- KROS 2020
- Fundamental
- Price
- LEU $77.73
- KROS $10.86
- Analyst Decision
- LEU Buy
- KROS Buy
- Analyst Count
- LEU 2
- KROS 11
- Target Price
- LEU $92.00
- KROS $45.33
- AVG Volume (30 Days)
- LEU 566.8K
- KROS 2.0M
- Earning Date
- LEU 02-06-2025
- KROS 02-26-2025
- Dividend Yield
- LEU N/A
- KROS N/A
- EPS Growth
- LEU 50.42
- KROS N/A
- EPS
- LEU 4.70
- KROS N/A
- Revenue
- LEU $394,000,000.00
- KROS $651,000.00
- Revenue This Year
- LEU $25.25
- KROS $303.39
- Revenue Next Year
- LEU $5.68
- KROS N/A
- P/E Ratio
- LEU $16.56
- KROS N/A
- Revenue Growth
- LEU 14.94
- KROS 8037.50
- 52 Week Low
- LEU $33.51
- KROS $9.78
- 52 Week High
- LEU $118.36
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- LEU 55.13
- KROS 20.25
- Support Level
- LEU $68.10
- KROS $9.78
- Resistance Level
- LEU $74.66
- KROS $16.49
- Average True Range (ATR)
- LEU 5.10
- KROS 0.92
- MACD
- LEU 0.66
- KROS 0.97
- Stochastic Oscillator
- LEU 65.97
- KROS 14.52
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.